Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue 4
Submit an article Journal homepage
987
Views
35
CrossRef citations to date
0
Altmetric
Psoriasis and Dermatitis

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

G. CarreteroHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Correspondence[email protected]
,
L. PuigHospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; ORCID Iconhttp://orcid.org/0000-0001-6083-0952
ORCID Icon,
J. M. CarrascosaHospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain; ORCID Iconhttp://orcid.org/0000-0003-4266-0771
ORCID Icon,
L. FerrándizHospital Universitario Virgen Macarena, Sevilla, Spain;
,
R. Ruiz-VillaverdeComplejo Hospitalario de Granada, Spain;
,
P. de la CuevaHospital Universitario Infanta Leonor, Madrid, Spain;
,
I. BelinchonHospital General Universitario de Alicante-ISABIAL, Alicante, Spain;
,
E. VilarrasaHospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain;
,
R. del RioFundació Hospital L’Esperit Sant, Santa Coloma de Gramenet, Spain;
,
J. L. Sánchez-CarazoConsorcio Hospital General Universitario de Valencia, Spain;
,
A. López-FerrerHospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain;
,
F. PeralHospital Universitario Infanta Cristina de Badajoz, Badajoz, Spain;
,
S. ArmestoHospital Universitario Marqués de Valdecilla, Santander, Spain;
,
N. EirisComplejo Asistencial Universitario de León, Spain;
,
J. MitxelenaComplejo Hospitalario de Navarra, Spain;
,
J. Vilar-AlejoHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain;
,
M. A. MartinHospital Clínico Universitario Lozano Blesa, Zaragoza, Spain;
,
C. SoriaHospital General Universitario Reina Sofia, Murcia, Spain
& from the Spanish Group of Psoriasis show all
Pages 334-346 | Received 21 Jun 2017, Accepted 18 Oct 2017, Published online: 21 Nov 2017

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Isabel Belinchon Romero, Almudena Mateu Puchades, Miguel Ribera Pibernat, Diana. P. Ruiz Genao, Pablo de la Cueva Dobao & Jose Manuel Carrascosa. (2023) Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. Annals of Medicine 55:1, pages 1335-1345.
Read now
Wolf-Henning Boehncke, Nicolo Costantino Brembilla & Michael John Nissen. (2021) Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Review of Clinical Immunology 17:1, pages 5-13.
Read now
Sascha Gerdes, Andreas Körber, Mona Biermann, Claudia Karnthaler & Maximilian Reinhardt. (2020) Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of Dermatological Treatment 31:5, pages 470-475.
Read now

Articles from other publishers (32)

Sonsoles Berenguer‐Ruiz, Mario Aparicio‐Domínguez, Pedro Herranz‐Pinto, Ricardo Ruíz‐Villaverde, Anna López‐Ferrer, Jorge Santos‐Juanes, Lourdes Rodríguez Fernández‐Freire, Mercedes Hospital‐Gil, Salvador Arias‐Santiago, Gregorio Carretero‐Hernández, Almudena Mateu‐Puchades, Marta Ferran, Elena del Alcázar, Sergio Santos‐Alarcón, Francisco Javier Garcia‐Latasa de Aranibar, Isabel Belinchón‐Romero, Álvaro González‐Cantero, Diana Ruíz‐Genao, Noemí Eiris‐Salvado, Vicenç Rocamora‐Durán, Raquel Rivera‐Diaz, Pablo de la Cueva, Esteban Daudén, Laura Salgado‐Boquete & Mar Llamas‐Velasco. (2023) Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology 37:12, pages 2517-2525.
Crossref
Cécile Philippoteaux, Anne Marty-Ane, Emeline Cailliau, Julien Labreuche, Peggy Philippe, Bernard Cortet, Julien Paccou, Rene-Marc Flipo & Jean-Guillaume Letarouilly. (2023) Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis. Seminars in Arthritis and Rheumatism 63, pages 152275.
Crossref
Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton & Marina Venturini. (2023) Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study). JEADV Clinical Practice 2:4, pages 739-752.
Crossref
E. Daudén, D. Vidal, A. Romero, M.T. Bordel, R. Rivera, J. Márquez, E. Zamora, L. Martinez, M.J. Ocaña, C. Vila, P. Iribarren, N. Corona & A. Zulaica. (2023) [Artículo traducido] Gravedad de la psoriasis, calidad de vida relacionada con la salud, productividad laboral y deterioro de la actividad en pacientes con psoriasis moderada a grave que reciben tratamiento sistémico: datos de la vida real de la práctica clínica en España. Actas Dermo-Sifiliográficas.
Crossref
L. Salgado-Boquete, S. Arias-Santiago, I. Belinchón-Romero, A. de la Cuadra-Grande, P. de la Cueva, Y. Gilaberte, J. Notario, R. Rivera-Díaz, R. Ruiz-Villaverde & J.M. Carrascosa. (2023) [Translated article] Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study. Actas Dermo-Sifiliográficas 114:10, pages T865-T883.
Crossref
L. Salgado-Boquete, S. Arias-Santiago, I. Belinchón-Romero, A. de la Cuadra-Grande, P. de la Cueva, Y. Gilaberte, J. Notario, R. Rivera-Díaz, R. Ruiz-Villaverde & J.M. Carrascosa. (2023) Proyecto CUDERMA: Consenso Delphi de los indicadores de calidad para la certificación de las unidades de dermatología de atención en psoriasis. Actas Dermo-Sifiliográficas 114:10, pages 865-883.
Crossref
Alin Codrut Nicolescu, Marius-Anton Ionescu, Maria Magdalena Constantin, Ioan Ancuta, Sinziana Ionescu, Elena Niculet, Alin Laurentiu Tatu, Henner Zirpel & Diamant Thaçi. (2022) Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life 12:12, pages 2050.
Crossref
T. Graier, W. Weger, C. Jonak, P. Sator, C. Zikeli, K. Prillinger, C. Sassmann, B. Gruber, W. Saxinger, G. Ratzinger, C. Painsi, A. Mlynek, N. Häring, B. Sadoghi, H. Trattner, R. Müllegger, F. Quehenberger, W. Salmhofer & Peter Wolf. (2022) Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Scientific Reports 12:1.
Crossref
J.M. Carrascosa, L. Puig, I. Belinchón Romero, L. Salgado-Boquete, E. del Alcázar, J.J. Andrés Lencina, D. Moreno & P. de la Cueva. (2022) [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. Actas Dermo-Sifiliográficas 113:3, pages T261-T277.
Crossref
J.M. Carrascosa, L. Puig, I. Belinchón Romero, L. Salgado-Boquete, E. del Alcázar, J.J. Andrés Lencina, D. Moreno & P. de la Cueva. (2022) Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica». Actas Dermo-Sifiliográficas 113:3, pages 261-277.
Crossref
Elena del Alcázar, Anna López‐Ferrer, Álvaro Martínez‐Doménech, Ricardo Ruiz‐Villaverde, Mª. del Mar Llamas‐Velasco, Vicenç Rocamora, Marc Julià, Jaime Notario, Lourdes Rodríguez Fernández‐Freire, Antonio Sahuquillo‐Torralba, David Vidal, Raquel Rivera, Gregorio Carretero, Almudena Mateu, Pablo Cueva & José Manuel Carrascosa. (2022) Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy 35:2.
Crossref
D. Thaçi, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams & P. Weisenseel. (2022) Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology 186:1, pages 30-39.
Crossref
K. Reich, U. Mrowietz, A. Menter, C.E.M. Griffiths, J. Bagel, B. Strober, N. Nunez Gomez, R. Shi, B. Guerette & M. Lebwohl. (2021) Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. Journal of the European Academy of Dermatology and Venereology 35:12, pages 2409-2414.
Crossref
Miquel Ribera, Laura Salgado-Boquete, Emilio Monte, Mar Llamas Velasco, Federico Palomar, Marta García Bustínduy, Sandra Ros, Estíbaliz Loza & Santiago Alfonso. (2021) Encuesta sobre el impacto, las necesidades actuales y las expectativas de los pacientes españoles con psoriasis. Encuesta NEXT. Piel 36:10, pages 648-656.
Crossref
Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi & Roberto Orsenigo. (2021) Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica 101:10, pages adv00576.
Crossref
Laura Salgado-Boquete, José Manuel Carrascosa, Mar Llamas-Velasco, Ricardo Ruiz-Villaverde, Pablo de la Cueva & Isabel Belinchón. (2021) A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?. Life 11:7, pages 627.
Crossref
Marloes E. van Muijen, S. Atalay, L. J. van Vugt, L. M. D. Vandermaesen, J. M. P. A. van den Reek & E. M. G. J. de Jong. (2021) Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. Drugs - Real World Outcomes 8:2, pages 163-172.
Crossref
Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku, Yayoi Tada, Shigetoshi Sano, Akimichi Morita, Shinya Sakurai, Naoki Hoshii, Nicola Tilt & Hidemi Nakagawa. (2021) Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results. Dermatology and Therapy 11:3, pages 943-960.
Crossref
G. Carretero, J.M. Carrascosa, L. Puig, J.L. Sánchez‐Carazo, A. López‐Ferrer, P. Cueva, C. Soria, R. Rivera & I. Belinchón. (2020) Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology 35:2, pages 422-430.
Crossref
C. A. J. Michielsens, M. E. van Muijen, L. M. Verhoef, J. M. P. A. van den Reek & E. M. G. J de Jong. (2021) Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. Drugs 81:3, pages 349-366.
Crossref
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, Stefano Piaserico, Paolo Amerio, Anna Balato, Federico Bardazzi, Piergiacomo Calzavara Pinton, Anna Campanati, Angelo Cattaneo, Paolo Dapavo, Clara De Simone, Valentina Dini, Maria C. Fargnoli, Maria L. Flori, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Ada Lo Schiavo, Piergiorgio Malagoli, Giovanna Malara, Santo R. Mercuri, Maria L. Musumeci, Luigi Naldi, Manuela Papini, Aurora Parodi, Concetta Potenza, Francesca Prignano, Franco Rongioletti, Luca Stingeni, Rossana Tiberio, Marina Venturini, Luca Bianchi, Antonio Costanzo, Francesco Cusano, Giampiero Girolomoni, Anna M. Offidani & Ketty Peris. (2021) Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy 11:1, pages 235-252.
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeysh, M. V. Shapina & O. B. Shchukina. (2020) Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion. Almanac of Clinical Medicine 48:6, pages 422-436.
Crossref
L. S. Kruglova, A. A. Hotko & M. Yu. Pomazanova. (2020) Issues of switching therapy when effect of biological genetically engineered drugs escapes. Medical alphabet:24, pages 48-52.
Crossref
Dario F. D'Urso, Andrea Chiricozzi, Federico Pirro, Laura Calabrese, Giacomo Caldarola, Barbara Fossati, Clara De Simone & Ketty Peris. (2020) New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano di Dermatologia e Venereologia 155:4.
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina & O. B. Shchukina. (2020) Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion. Modern Rheumatology Journal 14:3, pages 7-18.
Crossref
Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla, Christophe Sapin & Susanne Hartz. (2020) Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open 10:8, pages e032552.
Crossref
S.K. Mahil, N. WilsonN. DandN.J. ReynoldsC.E.M. GriffithsR. EmsleyA. Marsden, I. EvansR.B. WarrenD. StockenJ.N. BarkerA.D. BurdenC.H. Smith. (2019) Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR ) . British Journal of Dermatology 182:5, pages 1158-1166.
Crossref
Selma Atalay, Juul M. P. A. van den Reek, Alfons A. den Broeder, Lieke J. van Vugt, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje A. Berends, Peter C. M. van de Kerkhof, Hans M. M. Groenewoud, Wietske Kievit & Elke M. G. J. de Jong. (2020) Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis. JAMA Dermatology 156:4, pages 393.
Crossref
P.C.M. van de Kerkhof, R. Loewe, U. Mrowietz, M. Falques, I. Pau‐Charles & J.C. Szepietowski. (2019) Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate ( DMF ): a post hoc analysis of the BRIDGE study . Journal of the European Academy of Dermatology and Venereology 34:1, pages 119-126.
Crossref
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan & Andrew Blauvelt. (2019) Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet 394:10201, pages 831-839.
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. A. BelousovaL. F. Znamenskaya, T. V. Korotaeva, L. S. Kruglova, M. M. Kokhan, A. M. Lila, V. R. Khayrutdinov, I. L. Khalif & M. M. Khobeysh. (2018) A draft of the interdisciplinary guidelines for diagnosis, methods for assessment of the degree of inflammatory activity, therapeutic efficacy, and for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). Almanac of Clinical Medicine 46:5, pages 426-444.
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. А. Belousova, L. F. Znamenskaya, T. V. Korotaeva, L. S. Kruglova, M. M. Kokhan, A. M. Lila, V. R. Khairutdinov, I. L. Khalif & M. M. Khobeish. (2018) Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). Modern Rheumatology Journal 12:3, pages 4-18.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.